Clinical Outcomes and Adverse Effect Management of Sotorasib in a KRAS G12C Mutated NSCLC Patient

<p>Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, frequently driven by genetic mutations such as KRAS. This case report presents a 67-year-old female patient diagnosed with NSCLC of the right lung, harboring a KRAS G12C mutation. Initial treatment with stereotactic body radiotherapy (SBRT) and chemotherapy was poorly tolerated, leading to the administration of sotorasib, a KRAS G12C inhibitor. The patient experienced adverse effects including severe rash, diarrhea, and acid reflux, necessitating dose adjustments. This report details the clinical course, management strategies for adverse effects, and outcomes in the context of KRAS G12C-mutated NSCLC treated with sotorasib.</p>